Management of Primary Hyperparathyroidism
Surgery is the standard definitive treatment for primary hyperparathyroidism and should be offered to any patient meeting specific surgical criteria, while patients who don't meet these criteria or cannot undergo surgery should receive targeted medical management. 1
Surgical Indications (Grade A++)
Surgery should be proposed when any one or more of the following conditions are present 1:
- Bone involvement: T-score <–2.5 SD on bone densitometry at any site, OR proven low-energy fracture
- Kidney stones: Proven renal colic, urinary tract lithiasis, or nephrocalcinosis on imaging
- Renal impairment: eGFR or creatinine clearance <60 mL/min/1.73 m²
- Hypercalciuria: 24-hour urinary calcium >250 mg/day (6.25 mmol/day) in women or >300 mg/day (7.5 mmol/day) in men
- Severe hypercalcemia: Blood calcium level >0.25 mmol/L (>10 mg/L) above the upper limit of normal
Preoperative Imaging Algorithm
When surgery is planned, localization imaging is essential 1:
- First-line: Parathyroid ultrasound PLUS functional imaging (either 123I/99mTc-sestamibi SPECT or 18F-choline PET-CT)
- Second-line (if first-line negative): 18F-choline PET-CT if initial study was sestamibi
- Third-line (if still negative): 4D CT or MRI at an expert center 1
Important caveat: 18F-choline PET-CT is preferred first-line in young patients (<40 years), family history, or suspected multi-glandular disease 1
Surgical Approach
- Selective (focused) parathyroidectomy: For single-gland disease on imaging, with intraoperative PTH monitoring to confirm adequate resection 1
- Bilateral cervical exploration: Required for multi-glandular disease, negative imaging, hereditary forms, lithium-induced disease, or inadequate intraoperative PTH drop 1
Medical Management
For patients who refuse surgery, have surgical contraindications, or don't meet surgical criteria, the following medical approach should be implemented 1:
Baseline Management for All Non-Surgical Patients
- Calcium intake: 800 mg/day (women <50 years, men <70 years) or 1000 mg/day (women >50 years, men >70 years) - follow general population recommendations, NOT restriction
- Vitamin D: Target 25(OH)D >30 ng/mL with supplementation as needed
- Hydration: Maintain diuresis >2 liters/day 1
Targeted Pharmacotherapy
- Cinacalcet: Offer when calcium is >0.25 mmol/L above upper limit of normal 1
- Bisphosphonates (alendronate): For osteoporosis 1
- Denosumab: Specifically for radius bone involvement 1
Local Destruction (Ablation)
This is reserved for an extremely limited patient population and should only be considered after multidisciplinary board discussion 1:
- Appropriate candidates: Patients with surgical indications BUT absolute surgical contraindications (severe comorbidities, anesthetic contraindications), AND only after failure or intolerance of medical treatment
- NOT recommended: For patients who simply refuse surgery (recurrent nerve injury risk equals surgery) or those without surgical indications 1
Key Clinical Pitfalls
"Asymptomatic" is often misclassified: Many patients labeled asymptomatic actually have symptomatic disease when properly screened. Always check for 2:
- Vertebral fractures (spinal imaging)
- Nephrolithiasis (CT preferred over ultrasound)
- Bone mineral density at spine, femur, AND radius
Don't restrict calcium intake - this is a common error. Patients should follow normal population recommendations, not low-calcium diets 1
Vitamin D deficiency should be corrected even in hypercalcemic patients - target >30 ng/mL 1
Monitoring for Non-Surgical Patients
Patients not undergoing surgery require ongoing surveillance for development of surgical indications, as the disease can progress over time requiring reassessment of the treatment approach 2.